Amneal Makes Second US Biosimilar Launch With Filgrastim
Releuko Version Of Neupogen Follows Alymsys Bevacizumab Rival To Avastin
Executive Summary
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.
You may also be interested in...
Proud Amneal Offers Preview Of Q1 Growth
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
Amneal Says Vertical Integration Will Be Key To Compete In Biosimilars
Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.
Apobiologix Launches Pegfilgrastim Autoinjector In Canada
Apobiologix’s new Lapelga autoinjector that the firm has just introduced in Canada is only the second on-body pegfilgrastim device to launch after Amgen’s Neulasta original.